The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•13 February 2026•

1 min read

West Pharmaceutical (WST) Beats Q4 Estimates, Raises 2026 Guidance, and Announces SmartDose Sale

3D metallic 'PVH' text with 'CALVIN KLEIN' and 'TOMMY HILFIGER' names. Upward trend line, 'EARNINGS BEAT', 'REVENUE: +14%', and '2026 GUIDANCE' on an orange background.

West Pharmaceutical Services (WST) announced robust financial results for the fourth quarter and full-year 2025, exceeding analyst expectations for both earnings and sales. The company further bolstered investor confidence by issuing optimistic guidance for 2026, primarily driven by strong performance in its Proprietary Products segment and sustained HVP growth. In a strategic move, WST also revealed plans to divest its SmartDose 3.5ml product to AbbVie, with the transaction expected to conclude by mid-2026. This combination of strong current performance, a strategic divestiture, and a positive future outlook led to a notable increase in WST's stock price. The market reacted favorably to the company's strategic execution and promising financial trajectory.